Allergan Gets Regen Med Assets, Acelity Gets Cash Boost Post-IPO Dump
Executive Summary
Allergan has agreed to acquire Acelity's LifeCell division for $2.9bn. The deal will give Allergan entry to the regenerative medicine sector and expand its aesthetics portfolio, while the substantial cash consideration should console Acelity after ditching plans for an IPO.